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Abstract
Background: Decision makers have huge problems when attempting to attribute social value to the improvements
achieved by new drugs, especially when considering the use of orphan drugs for rare diseases. We present the
results of a pilot study aimed to investigate patient preferences regarding public funding for drugs used to treat
rare diseases.
Methods: An online questionnaire was used as a discrete choice experiment (DCE) survey to explore the
preferences of patients with cystic fibrosis and haemophilia in Italy. The questionnaire focused on relevant issues
that were defined in a review of the literature. A conditional logistic model showed preferences for specific
attributes.
Results: A total of 54 questionnaires (20% response rate) were completed. The issues that received the greatest
attention were improvement in health, treatment cost and value for money. However, disease severity and the
availability of other treatments were important social values that could not be ignored.
Conclusions: The findings presented here provide evidence as to what patients with cystic fibrosis or haemophilia
think are the most important considerations on which to base decisions in health technology scenarios, and
regarding the priorities for funding.
Keywords: Discrete choice experiment, Cystic fibrosis, Haemophilia, Decision making, Rare disease, Orphan drugs,
Italy
Background
Since the price and effectiveness of therapies for rare
diseases often suggest they are unlikely to provide value
for money, in some countries it may be necessary to use
additional criteria when assessing reimbursement, in-
cluding disease severity, improvement in health and the
availability of alternative treatments [1]. Drug pricing is
a national competence exercised by the Italian medicines
agency (AIFA). Orphan drug regulations follow the same
indications of all other medicines. The price at which a
medication will eventually be reimbursed by the Na-
tional Healthcare System (NHS) is the result of a negoti-
ation between the company requesting the medicine
market access in Italy and AIFA. Indeed, in such circum-
stances multi-criteria decision analysis (MCDA) repre-
sents a useful aid to decision-making. In MCDA, the
relative importance and the influence of each criterion
on the final decision is defined [2]. Although MCDA are
not commonly employed in health technology assess-
ment, they are important aids to decision-making when
establishing health priorities and as such, they are being
encountered more frequently [3, 4]. Indeed, when mul-
tiple conflicting criteria, goals or objectives have to be
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taken into account, MCDA are increasingly recognised
as a valuable aid when faced with complex decisions. As
a result, one MCDA technique has become increasingly
popular, the Discrete Choice Experiment (DCE). This
approach can provide stated-preference information, in-
dicate whether particular attributes are predictors of
choice in different scenarios, as well as assess the relative
importance of the attributes used to describe the alter-
natives in choice sets [5]. There is evidence that a DCE
approach may be suitable to establish general prefer-
ences and to guide priorities in healthcare provisions [5,
6]. Indeed, establishing a decision-making framework
that extends beyond Cost-QALY approach and that
takes into account additional criteria may well represent
a fairer system in the context of rare diseases.
In the light of the above, a pilot study has been carried
out to determine the preferences of cystic fibrosis and
haemophilia patients in Italian registries regarding health-
care interventions, and particularly in reference to generic
social value judgments. The study uses a DCE framework
to consider the patient’s preferences and it specifically ex-
plores how patients may weigh up competing distributive
preferences in a priority-setting context.
Methods
A DCE was carried out in accordance with previously
used methods [5]. More details about the design are pro-
vided elsewhere [7]. The study followed the approach
recommended by Street and Burgess [8].
Attributes and levels
A systematic review of the empirical literature on distribu-
tive preferences was carried out to inform the attribute se-
lection [9]. This literature review aimed to identify the
specific attributes suitable to design a DCE for rare dis-
eases that would help develop and validate a framework to
support decision-making. Attributes were selected based
on the frequency of their use in rare disease-related litera-
ture. The following attributes were chosen: improvement
in health; treatment cost; side effects; waiting time; disease
severity; availability of other treatments; and value for
money. This list was discussed with methodological ex-
perts and healthcare decision-makers to confirm the valid-
ity of the criteria selected. Finally, we defined eight
attributes; seven identified through the literature review
and one more recommended by the expert panel: begin-
ning of life (i.e. patients younger than 10 years of age).
The relative importance of each criterion was assessed in
a pre-pilot study carried out to achieve an attribute ranking,
which helped define the best way to present the informa-
tion. Based on a descriptive analysis of the results obtained
and another round of discussion with the expert panel, the
final attribute selection was made. Then, a formal pilot
study was carried out using an interview between a random
sample of the expert panel, and most of the respondents in-
dicated that they could understand and complete the ques-
tions. Indeed, the respondents provided positive comments
regarding the level of understanding and their commit-
ment. The selection of the attribute levels took into account
two main criteria: first, to preserve the number of evidence-
based attributes given their importance in the decision-
making process; and second, to ensure the feasibility of the
experimental design. In Table 1, the attributes selected, and
the specific levels are described.
Experimental design
An orthogonal, main-effects design was adopted that in-
cluded 36 pairs of scenarios distributed into two equal sized
blocks. Each scenario described a combination of attributes
and levels, with known efficiency, and it used fold-over cop-
ies to create the necessary subsequent choices. The design
assumed that interactions among the attributes were insig-
nificant in all the two-way and higher-order interactions
[5]. A blocking approach was selected to limit respondent
burden, and the design was balanced evenly across the
Table 1 Discrete choice experiment attributes and levels
Attribute Levels
Disease Severity Moderate
Severe
Health Improvement Large
Moderate
Small
Very small
Waiting times Short
Moderate
Long
Availability of other treatments Yes
No
Side effects Few
Moderate
Many
Value for money Very good
Fairly good
Fairly poor
Very poor
Beginning of life Yes
No
Treatment Cost Zero
Low
Moderate
High
Source: a full explanation of attributes and levels are provided on Lopez-
Bastida, et al. (2018) [7]
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blocks. Respondents were asked to make a series of choices
involving two alternative healthcare scenarios (paired com-
parisons).
The design used had level balance and was orthog-
onal, minimising multicollinearity. All of the scenarios
used were checked for plausibility, i.e. the potential
that health technologies would fit the scenarios. The
choices were blocked into two sets of 18 choices to
avoid the respondent burden, for two versions of the
questionnaire. The blocking into two sets of questions
was undertaken using an additional attribute column
from the factorial design employed, to ensure orthog-
onality over the choice set.
Sample/data collection
Researchers participating in the ADVANCE-HTA Pro-
ject (Italy) contacted cystic fibrosis or haemophilia pa-
tients from the registries of existing Italian Haemophilia
and Cystic Fibrosis Associations. The Italian registry of
CF counts with 5362 patients and 120 were invited to
complete the questionnaire. The Italian federation of
haemophilia (FEDEMO), which includes 32 Italian local
association counts with 9000 haemophilia patients. The
haemophilia association invited 150 patients to answer
the questionnaire. The patients were invited to partici-
pate directly by their patient’s associations and they were
asked to complete an online questionnaire. Data were
also collected during control visits to hospitals (in par-
ticular for Cystic Fibrosis patients). The attributes and
levels were presented as features of health technologies,
and the patients were asked to put themselves in the
context of a health service decision-maker faced with
difficult decisions in a priority setting. One of the two al-
ternative scenarios in each choice set had to be selected
since the decision-maker was unable to fund all of the
health technologies (Fig. 1 shows an example of one
question in the survey).
There is limited consensus on sample size calculations
for discrete choice studies, and there are no well-
designed, practical rules to guide the analyst [10, 11].
Thus, we tried to maximise the sample size, obtaining a
minimum of 20 responses per block to obtain sufficient
variance in the estimated choice probabilities.
Fig. 1 Example of a survey question
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Data analysis
A descriptive analysis was used to present the background
characteristics of the respondents. Means and standard
deviation were used for continuous variables, and propor-
tions for dichotomous variables. The responses variables
were categorised in two values, ‘1’ represented the option
being chosen and ‘0’ the one not chosen. Following Mcfa-
den’s framework based on the random utility theory, pref-
erences estimates rest on the assumption that when
participants chose scenario A over scenario B, scenario A
gave them a higher utility. Accordingly, a conditional lo-
gistic model can be applied, and the coefficients of the
model represent the relative weights of each level of each
attribute, allowing the interpolation or extrapolation of
the utilities not observed within the population [11, 12].
In other words, the coefficients of the model can be inter-
preted to define the relative importance that the sample
gave to the movement of any given attribute from the ref-
erence level to a different level. Given the coding of the
levels by attribute (a = reference case, b = 1, c = 2 and so
on), positive and negative coefficients could arise. For ex-
ample, for the attribute related to the availability of alter-
native treatments, the reference case (a) is “Yes”, so that
the coefficient of level b will show the change in the utility
when moving from “Yes” to “No”. In this case, we expect a
positive coefficient, and if there is no other existing treat-
ment, the chance of being funded would be higher. How-
ever, for the attribute related to disease onset at the
beginning of life, the opposite is the case, and we would
expect a negative coefficient. Finally, an exclusion criterion
was applied for respondents who took 200 s or less to
complete the survey in order to eliminate random (non-
meaningful) responses. All statistical analyses were per-
formed using STATA MP [13].
Results
A total of 54 questionnaires were completed (20% re-
sponse rate), and of these, eight were excluded from the
analysis as they failed to comply with the exclusion criteria
described in the method section. Thus, the valid sample
comprised of 46 patients, the main characteristics of
which are shown in Table 2. The sample sizes by block
surpassed our expectations (> 20 respondents), although
the exclusion criteria removed six respondents from block
2 and two respondents from block 1 (Table 2).
The observed choice probabilities ranged from 30.43 to
69.5%, which means that different decisions will be made
for an individual scenario depending on who makes the
decision, with no clear preferences among the patients.
The coefficients in Table 3 reflect the partial worth util-
ities associated with changes in each of the attribute levels
(compared to the reference case). For example, a health
technology scenario with a large improvement in health
has a higher utility/preference than scenarios with a small
or moderate improvement in health, all else being equal.
Each logit model coefficient showed similar patterns, with
many coefficients close to 0 due to the response of the
model to the observed probabilities. The closer the prob-
abilities are to 50%, the smaller the expected distance be-
tween the two options in the DCE for that utility.
Accordingly, the improvements in health, treatment cost
and value for money were the attributes that received the
Table 2 Characteristics of participants in the DCE
Before exclusion criteria (n = 54) After exclusion criteria (n = 46)
Age, mean (SD) 38.98 (10.27) 38.36 (9.24)
Household members, mean (SD) 2.72 (1.28) 2.65 (1.22)
Self-reported health status, %
Good 66.67 71.74
Average 7.41 4.35
Poor 25.93 23.91
Patients answering block 1, n (%) 25 (46.29) 23 (50)
Patients answering block 2, n (%) 29 (53.7) 23 (50)
Interview durationa, mean (SD) 415.1 (301.45) 460.21 (304.42)
Task timea, mean (SD) 21.21 (50.48) 23.66 (54.3)
Were the questions easy to understand? (%)
Agree 40.7 47.8
Mildly agree 31.5 32.6
Indifferent 11.1 10.9
Mildly disagree 11.1 6.5
Disagree 5.6 2.2
aTime in seconds
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most attention from patients, while disease severity and
the availability of other treatments were less important to
these patients (Table 3). The model fits the observed
probabilities well (i.e., those included in the DCE de-
sign), and the models do not show probability inver-
sions. The range of the probabilities, showing the
uncertainty in the estimates.
Discussion
When making priority-setting decisions, policymakers
are often faced with difficult choices between options
that can each be regarded as potentially beneficial. How-
ever, a range of social values will influence policy deci-
sions, and when there are trade-offs between such social
values, or equity arguments (objectives), the judgment
must be made as to which is the best decision.
In recent years, several frameworks have been prepared
in which an MCDA guides reimbursement decision-
making for orphan drugs [13–16]. Here, a pilot MCDA
study was used to establish a framework of weighted attri-
butes that could serve to attribute value to orphan medi-
cinal products. From the results obtained, it is clear that
this type of approach could be developed further to aid
health technology assessment bodies and payers.
No previous studies focus on cystic fibrosis or
haemophilia have been found. Thus, the findings pre-
sented here provide evidence as to how patients with
cystic fibrosis and haemophilia think that decisions
should be made in Italy regarding which health tech-
nology (orphan drugs) scenarios are worthier of
receiving funds. Improvements in health, treatment
cost and value for money are the attributes that re-
ceived the most significant attention of patients with
these rare diseases, while disease severity and the
availability of other treatments were less important to
these patients. There may be a link that both diseases
are genetic/inherited that may influence the results.
The most important attributes for this group of patients
have similarities with the group of decision-makers that we
have tested in a similar study [7]. In addition, the results in
this study are in line with earlier work from England, where
face-to-face interviews were used on a sample from the
general population, and where improvement in health and
value for money were the attributes that provided the
strongest indication of social value (preference) [5].
This is valid information that can be used to design fu-
ture Bayesian-based DCE designs. Indeed, the informa-
tion gathered here could serve to inform an efficient
Bayesian design in order to obtain a general algorithm
that would help make a uniform decision across the
healthcare system.
This study has some limitations, reflecting its explora-
tive nature. The experimental design used was not com-
plex, with a small factorial design used, and the results
presented here are based on a simple analytical frame-
work, using a conditional logistic model. Both of these fac-
tors are deliberate to ensure that the findings are policy-
relevant and that they are presented in a policy friendly
manner, although they do represent potential limitations.
As an exploratory study, we sought to keep the
Table 3 Logit model coefficients
Attribute Level Model framework
Logit coefficients Confidence interval (95%)
Severity of the disease (reference =moderate) Severe disease 0.005 −0.309-0.318
Improvement in health (reference = large) Moderate −0.425 − 0.949-0.098
Small −0.369 − 0.925-0.186
Very small −0.070 −0.353-0.213
Waiting times (reference = short) Moderate −0.102 −0.383-0.18
Long 0.020 −0.256-0.296
Availability of other treatment (reference = yes) No −0.008 −0.303-0.286
Side effects (reference = few) Moderate −0.079 −0.37-0.213
Many −0.002 −0.286-0.282
Value for money (reference = very good) Fairly good −0.285 −0.753-0.182
Fairly poor −0.042 0–0
Very poor −0.301 −0.629-0.028
Beginning of life (refeence = yes) No 0.158 −0.085-0.401
Cost of treatment (measured by tax increase / copayments)
(reference = none)
Low 0.396 −0.13-0.922
Moderate 0.361 −0.09-0.811
High 0.112 −0.241-0.465
None of this coefficient was statistically significant
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experimental design straightforward, albeit in the know-
ledge that these preliminary findings could be used to in-
form more detailed future study designs. The attributes
considered covered issues that were expected to be very
common in priority-setting dilemmas, such as technology
assessment. However, some patients may think that their
specific health problems are not covered by the criteria
used. Of course, other attributes could be introduced to
make the scenarios more context specific. Indeed, a fur-
ther limitation of the study is the absence of objective data
on the seriousness of the response for the sample due to
the use of an internet-based strategy. Given the time re-
quired to complete the survey, in some cases, we are less
confident about the quality of the responses. Nevertheless,
we did try to correct for this possible bias by excluding
the very short surveys.
It is also possible that the sample provides a good rep-
resentation of the rare disease patient in Italy and while
it is relatively small, it does appear to provide some indi-
cation of the extent to which the findings can be gener-
alised. Indeed, the feedback from interviewers from the
pilot study (expert panel) and the main survey (patients)
was that the respondents were keen to participate, they
seemed engaged in the survey, and generally, they had
few problems completing the survey.
As with most empirical studies of this type, the
study is also open to some level of criticism regarding
the presentation, framing and the contextual approach
adopted. However, it does appear that the results are
useful and indicative of what may be possible if more
comprehensive research initiatives of this nature were
carried out. Other ways of administering surveys
should also be examined in such explorative study,
such as face to face interviews, which may shed light
on how respondents think when they are completing
the task. More importantly, such approaches may help
gain engagement with the research through a good
structure personal presentation. Thus, an increase in
interviewer-administered DCE would represent a clear
development, and accordingly, future work should ex-
plore the inclusion of interactions in the design and
analysis stages of a DCE. On the other hand, it has
been recently published a high sample size DCE study
where the participants who completed the DCE also
using an online tool. The authors concluded that in-
cluding overlap when presenting the choices or using
different colours for each level could make more ac-
cessible for participants to identify the differences be-
tween levels and moreover it seems that combining
colour editing levels plus overlap reduced the dropout
rate [17]. In our study, the dropout rate and the partici-
pants who stated the DCE “was easily understood” were
very low. We are in line with Jonker et al. and we think that
using overlap or maybe colour editing our comprehension-
related problem of some participants who took the DCE
could be solved.
Conclusions
This study adds to the relatively sparse literature on the
use of DCE methods to explore preferences about health
service funding. The information presented here could
be useful for future research designs following similar
approaches. Nested designs using partial profile presen-
tation should be explored to gain in both the under-
standing of individual preference and in the clarity of
the questions presented. The feasibility and acceptability
of the DCE approach to determine patient preferences
over priority-setting scenarios for healthcare provision
has several limitations, mostly due to the heterogeneity
in the preferences stated. However, several consider-
ations should be made in order to design an appropriate
experiment and in particular, we highlight the need to
use “face to face interviews instead of online surveys”.
The results of a DCE could be an additional HTA policy
tool in the assessment of the price and reimbursement
dossiers for orphan drugs in Italy.
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